NEWS!
- 04/2024
The facility restarts for 2024!
- 02/2024
David Townsend, co-inventor of the PET-CT visited MEDICIS
- 11/2023
Peter Thomson CEO of NPL and colleagues visited MEDICIS and discussed on the metrological aspects important for medical isotopes.
- 10/2023
The five-years MEDICIS programme and operation was very successfully reviewed by a CERN international review panel.
- 06/2023
MEDICIS recent achievements have been presented during invited presentations at the ARIS2023 conference (Avignon, France) and the 16th conference on nuclear reaction mechanisms (Varenna, Italy)
- 16/05/2023
Recent technical developments such as the online activity monitoring during implantation and the definition of Key Performance Indicators for MEDICIS were reported at EMIS2022 and IPAC2023 conferences. Related EMIS and IPAC publications.
- 10/03/2023
Three new project proposals were submitted at the 10th MEDICIS Collaboration board, with a notable request to translate one of the MEDICIS High Molar Activity radionuclides in a clinical settings.
- 15/11/2022
The Frontiers Research Topics : MEDICIS-Promed, Advances in Radioactive Ion Beams for Nuclear Medicine is now published. It can be downloaded from there.
- 26/09/2022
The half-life of Tb-155 produced at MEDICIS has been revised and is now published by S. Collins et al. in Applied Radiation and Isotope. High molar activity Sm-153 was 1st used in Targeted Radionuclide Therapy and theranostics (MED-025) by M. Ooms et al, as presented at TERACHEM.
JOB OPPORTUNITIES
- Two positions at JRC-Geel in Belgium, one for a physicist, another one for a (radio)chemist. The second one is key for securing target preparation for nuclear physics and nuclear data measurements in Europe.To apply: https://recruitment.jrc.ec.europa.eu/showprj_iframe.php?id=2777rope.
A KNOWLEDGE TRANSFER SUCCESS STORY
GRANTS & DONATIONS - CERN & Society Foundation
The CERN KT-Fund
La Fondation pour l'innovation sur le cancer et la biologie
The ADAM company
The FWO